STOCK TITAN

Agios Pharmaceuticals Inc - AGIO STOCK NEWS

Welcome to our dedicated news page for Agios Pharmaceuticals (Ticker: AGIO), a resource for investors and traders seeking the latest updates and insights on Agios Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Agios Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Agios Pharmaceuticals's position in the market.

Rhea-AI Summary
Agios Pharmaceuticals, Inc. will present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024. The presentation will focus on the company's pioneering therapies for rare diseases in the field of cellular metabolism.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.12%
Tags
conferences
-
Rhea-AI Summary
Agios Pharmaceuticals, Inc. reported positive results from Phase 3 ENERGIZE Study of Mitapivat in Thalassemia and Phase 2 RISE UP Study in Sickle Cell Disease. Two more Phase 3 readouts expected in 2024. U.S. PYRUKYND® net revenue was $7.1 million in Q4 with cash reserves of $806.4 million as of Dec. 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.47%
Tags
earnings
-
Rhea-AI Summary
Agios Pharmaceuticals, Inc. (AGIO) will host a conference call and live webcast to report its Q4 and year-end 2023 financial results and business highlights on February 15, 2024. The company specializes in cellular metabolism therapies for rare diseases and is a Nasdaq-listed leader in the field. The live webcast can be accessed on the company's website, with a replay available for at least two weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
conferences earnings
Rhea-AI Summary
Agios Pharmaceuticals, a leader in cellular metabolism pioneering therapies for rare diseases, announced positive Phase 3 data for its lead PK activator, mitapivat, in non-transfusion-dependent thalassemia, with potential FDA approvals in thalassemia in 2025 and sickle cell disease in 2026. The company expects four additional Phase 3 readouts by the end of 2025 and has a strong cash position to support its ongoing programs and disciplined pipeline expansion at least into 2026. Agios has achieved significant milestones in 2023 and anticipates several more in 2024, positioning the company for potential launches of first- and best-in-class therapies in the near future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.66%
Tags
none
-
Rhea-AI Summary
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) announced that the global Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary endpoint of hemoglobin response. Statistical significance was also achieved for both key secondary endpoints associated with change from baseline in FACIT-Fatigue Score and hemoglobin concentration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.21%
Tags
clinical trial
-
Rhea-AI Summary
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
conferences
Rhea-AI Summary
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) presented Phase 2 RISE UP study results of mitapivat for sickle cell disease at ASH 2023. Mitapivat demonstrated significant improvement in hemoglobin response and sickle cell pain crises. The Phase 3 dose has been selected, with a goal of reporting Phase 3 data in 2025 and potential U.S. approval in 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) announced that 40% of low transfusion burden cohort achieved transfusion independence in the Phase 2a study of investigational pyruvate kinase (PK) activator AG-946 for anemia in adults with lower-risk myelodysplastic syndromes (LR-MDS). The safety profile was consistent with healthy volunteer study data. Agios plans to initiate Phase 2b study mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.41%
Tags
clinical trial
-
Rhea-AI Summary
Agios Pharmaceuticals announces that both Mitapivat dose arms achieved statistically significant hemoglobin response in the Phase 2 portion of the RISE UP study in Sickle Cell Disease. Additional data on diseases like Pyruvate Kinase (PK) Deficiency and Thalassemia will be presented at the ASH Annual Meeting. Agios will also showcase its patient-centric approach to sickle cell disease clinical trials. Preclinical data for AG-946 suggests improvements in ineffective erythropoiesis in a model of Myelodysplastic Syndromes. Agios will host a live and webcast investor event on Dec. 11, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
conferences
Rhea-AI Summary
Agios Pharmaceuticals reports Q3 net revenue of $7.4 million and cash reserves of $872.4 million as of September 30, 2023. The company dosed the first patient in the Phase 3 portion of the RISE UP study for mitapivat in sickle cell disease. Enrollment in the Phase 3 ACTIVATE-Kids study of mitapivat in PK deficiency is complete. Agios expects data readouts in two Phase 3 trials of mitapivat in thalassemia next year and topline data for AG-946 in LR-MDS by year-end 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
earnings
Agios Pharmaceuticals Inc

Nasdaq:AGIO

AGIO Rankings

AGIO Stock Data

1.96B
47.62M
1.59%
109.2%
13.13%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About AGIO

at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible